Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AbbVie is conducting a Phase 3 clinical study to evaluate the efficacy, safety, and tolerability of ubrogepant for the preventive treatment of menstrual migraine. This study, titled ‘A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine With an Open-Label Extension,’ aims to assess adverse events and changes in disease activity among adult participants with menstrual migraines.
The study is testing ubrogepant, an investigational oral drug intended for the short-term prevention of menstrual migraines. Participants will receive either ubrogepant or a placebo, with the treatment administered daily for seven days starting three days before the estimated onset of menses.
This interventional study is randomized and follows a sequential intervention model with quadruple masking, involving participants, care providers, investigators, and outcomes assessors. The primary purpose is treatment-focused.
The study began on September 10, 2024, with primary completion expected in the near future. The last update was submitted on August 4, 2025. These dates are crucial for tracking the study’s progress and upcoming results.
The outcome of this study could significantly impact AbbVie’s stock performance and investor sentiment, especially if ubrogepant proves effective. It could also influence the competitive landscape in the migraine treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.